Cost-effectiveness of efavirenz vs rilpivirine in HIV patients initiating first-line combination antiretroviral therapy

Journal of Medical Economics

Volumn 16, Issue 4, 2013, Pages 552-559

  Bonafede, MacHaon ^a   Juday, Timothy ^b   Lenhart, Greg ^a   Pan, Katy ^a   Hebden, Tony ^b   Correll, Todd ^b  

^a Thomson Reuters   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Cost effectiveness; Efavirenz; HIV; Rilpivirine; Treatment guidelines

Indexed keywords

EFAVIRENZ; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL THERAPY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; MALE; MORTALITY; PATIENT ATTITUDE; SENSITIVITY ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; BENZOXAZINES; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; LIFE EXPECTANCY; MARKOV CHAINS; MODELS, ECONOMIC; NITRILES; PYRIMIDINES; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84875713663     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.774280     Document Type: Article

References (21)

1. Boyle BA, Jayaweera J, Witt MD, et al. Randomization to once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppression. HIV Clin Trials 2008;9:164-76
2. Kress KD. HIV update: emerging clinical evidence and a review of recommendations for the use of highly active antiretroviral therapy. Am J Health Syst Pharm. 2004;61(suppl 3):S3-S14
3. Brogan AJ, Talbird SE, Cohen C. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatmentna? ̈ve adults with HIV infection in the United States. Value in Health 2011; 14:657-64
4. Hogg RS, Bangsberg DR, Lima VD, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 2006;3:e356
5. Smith CJ, Lampe FC, Youle M, et al. Treatment discontinuation and virological failure amongst HIV-positive individuals starting second-line combination antiretroviral therapy (cART). J Int AIDS Soc 2008;11(Suppl 1):O37
6. Department of Health and Human Services (DHHS). Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. March 27, 2012; 1-240. http://aidsinfo.nih.gov/guidelines. Accessed April 2012
7. Food and Drug Administration. Antiretroviral drugs used in the treatment of HIV infection. 2012. http://www.fda.gov. Accessed January 2013
8. Portsmouth SD, Osorio J, McCormick K, et al. Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged release capsules. HIV Medicine 2005;6:185-90
9. Cohen C, Molina J, Cassetti I, et al. Pooled week 96 efficacy, resistance, and safety results from the double-blind, randomised, phase III trials comparing rilpivirin (RPV, TMC278) versus efavirenz (EFV) in treatment-naive, HIV-1-infected adults. Poster Presentation at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, July 17-20, 2011; Rome, Italy
10. Cohen C, Molina JM, Cahn P, et al. Pooled week 48 safety and efficacy results from the echo and thrive phase III trials comparing TMC278 vs EFV in treatment-naive, HIV-infected patients. Oral Presentation 0432. Presented at: The XVIII International AIDS Conference; July 18-23, 2010; Vienna, Austria
11. Bristol Myers Squibb Co. Atripla package insert. Plainsboro, NJ. June 2012
12. Gilead Sciences. Complera package insert. Foster City, CA. Revised August 2012
13. Heron M, Hoyert DL, Murphy SL, et al. Deaths: final data for 2006. Natl Vital Stat Rep 2009;57:1-134
14. Lewden C, Chene G, Morlat P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007;46:72-7
15. Sonnenberg FA, Beck JR, Markov models in medical decision making. Medical Decision Making 1993, p 329
16. World Health Organization (WHO). Guide to cost-effectiveness analysis. Tan-Torres Edejer T, Baltussen R, Adam T, et al., editors. Geneva, Switzerland: WHO; 2013; 45-8
17. Microsoft. Microsoft Excel. Redmond, Washington: Microsoft, 2010. Computer Software
18. Sanders GD, Bayoumi AM, Sundaram S, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 2005;352:570-85
19. Heart Protection Study Collaborative Group. Statin cost-effectiveness in the United States for people at different vascular risk levels. Circ Cardiovasc Qual Outcomes 2009;2:65-72
20. Bishai D, Haberlen S, Spacek L, et al. Comparing the cost-effectiveness of first-line HAART regimens. Poster P10.4/06 presented at 11th European AIDS Conference (EACS), October 24-27, 2007; Madrid, Spain
21. World Health Organization (WHO). HIV drug resistance fact sheet. April 2011; www.who.int/hiv/. Accessed January 2012